It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Peritoneal dialysis (PD) patients are at high risk for peritonitis, an infection of the peritoneum that affects 13% of PD users annually. Relying on subjective peritonitis symptoms results in delayed treatment, leading to high hospitalisation costs, peritoneal scarring, and premature transition to haemodialysis. We have developed and tested a low-cost, easy-to-use technology that uses microscopy and image analysis to screen for peritonitis across the effluent drain tube. Compared to other technologies, our prototype is made from off-the-shelf, low-cost materials. It can be set up quickly and key stakeholders believe it can improve the overall PD experience. We demonstrate that our prototype classifies infection-indicating and healthy white blood cell levels in clinically collected patient effluent with 94% accuracy. Integration of our technology into PD setups as a screening tool for peritonitis would enable earlier physician notification, allowing for prompt diagnosis and treatment to prevent hospitalisations, reduce scarring, and increase PD longevity. Our findings demonstrate the versatility of microscopy and image analysis for infection screening and are a proof of principle for their future applications in health care.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Stanford University, Department of Bioengineering, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Icahn Institute of Medicine at Mount Sinai, Department of Immunology, New York City, USA (GRID:grid.416167.3) (ISNI:0000 0004 0442 1996)
2 Stanford University, Department of Bioengineering, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
3 The Mount Sinai Hospital, Department of Nephrology, New York City, USA (GRID:grid.416167.3) (ISNI:0000 0004 0442 1996)
4 Stanford University, Department of Pediatrics, Division of Nephrology, Lucile Packard Children’s Hospital, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956)